Phase 1 study of molibresib (GSK525762), a bromodomain and extra-terminal domain protein inhibitor, in NUT carcinoma and other solid tumors

Sarina A. Piha-Paul, Christine L. Hann, Christopher A. French, Sophie Cousin, Irene Braña, Phillippe A. Cassier, Victor Moreno, Johann S. de Bono, Sara Duckworth Harward, Geraldine Ferron-Brady, Olena Barbash, Anastasia Wyce, Yuehui Wu, Thierry Horner, Meg Annan, Nigel J. Parr, Rabinder K. Prinjha, Christopher L. Carpenter, John Hilton, David S. HongNaomi B. Haas, Mark C. Markowski, Arindam Dhar, Peter J. O’Dwyer, Geoffrey I. Shapiro

Research output: Contribution to journalArticlepeer-review

Fingerprint Dive into the research topics of 'Phase 1 study of molibresib (GSK525762), a bromodomain and extra-terminal domain protein inhibitor, in NUT carcinoma and other solid tumors'. Together they form a unique fingerprint.

Medicine & Life Sciences